Home » Biosciences » Molecular Biology » Pecorino: Molecular Biology of Cancer 2e » Student resources » Hyperlinked bibliography » Chapter 12
Pecorino: Molecular Biology of Cancer 2e
Chapter 12
Further reading
Arteaga, C.L. and Baselga, J. (2003) Clinical trial design and end point for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin. Cancer Res. 9: 1579-1589. [PubMed: 12738709]
Benson, J.D., Chen, Y.-N.P., Vornell-Kennon, S.A., Dorsch, M., Kim, S., Leszczyniecka, M., Sellers, W.R., and Lengauer, C. (2006) Validating cancer drug targets. Nature 441: 451-456. [DOI: 10.1038/nature04873]
Druker, B.J. (2002) STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med. 8: S14-S18. [PubMed: 11927282] [DOI: 10.1016/S1471-4914(02)02305-5]
Klebe, G. (2006) Virtual ligand screening: strategies, perspectives, and limitations. Drug Discov. Today 11: 580-594. [PubMed: 16793526] [DOI: 10.1016/j.drudis.2006.05.012]
Romer, J. and Curran, T. (2005) Targeting medulloblastoma: small-molecule inhibitors of the sonic hedgehog pathway as potential cancer therapeutics. Cancer Res. 65: 4975-4978. [PubMed: 15958535] [DOI: 10.1158/0008-5472.CAN-05-0481]
Schiller, J.H. (2004) Clinical trial design issues in the era of targeted therapies. Clin. Cancer Res. 10: 4281S-4282S. [PubMed: 15217975] [DOI: 10.1158/1078-0432.CCR-040008]
Schulz, K.F. and Grimes, D.A. (2005) Sample size calculations in randomized trials: mandatory and mystical. Lancet 365: 1348-1353.
Strausberg, R.L., Simpson, A.J.G., Old, L.J., and Riggins, G.J. (2004) Oncogenomics and the development of new cancer therapies. Nature 429: 469-474. [PubMed: 15164073] [DOI: 10.1038/nature02627]
Weisberg, E., Manley, P.W., Cowan-Jacob, S.W., Hochhaus, A., and Griffin, J.D. (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia. Nature Rev. Cancer 7: 345-356. [DOI: 10.1038/nrc2126]
Selected Special Topics
Capdeville, R., Buchdunger, E., Zimmermann, J., and Matter, A. (2002) Glivec (STI571, Imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discov. 1: 493-502. [DOI: 10.1038/nrd839]
Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capedeville, R., Ohno-Jones, S., and Sawyers, C.L. (2001) Efficiency and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J. Med. 344: 1031-1037. [DOI: 10.1056/NEJM200104053441401]
Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., and Sawyers, C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification. Science 293: 876-880. [PubMed: 11423618] [DOI: 10.1126/science.1062538]
Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Huluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., and Haber, D.A. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J. Med. 350: 2129-2139. [DOI: 10.1056/NEJMoa040938]
Maser, R.S., Choudhury, B., Campbell, P.J., Feng, B., Wong, K.-K., Protopopov, A., O'Neil, J., Gutierrez, A., Ivanova, E., Perna, I., Lin, E., Mani, V., Jiang, S., McNamara, K., Zaghlul, S., Edkins, S., Stevens, C., Brennan, C., Martin, E.S., Wiedemeyer, R., Kabbarah, O., Nogueira, C., Histen, G., Aster, J., Mansour, M., Duke, V., Foroni, L., Fielding, A.K., Goldstone, A.H., Rowe, J.M., Wang, Y.A., Look, A.T., Stratton, M.R., Chin, L., Futreal, P.A., and DePinho, R.A. (2007) Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447: 966-971. [PubMed: 17515920] [DOI: 10.1038/nature05886]
Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., and Meyerson, M. (2004) EGFR mutations in lung cancer: correlation with clinical response to Gefitinib therapy. Science 304: 1497-1500. [PubMed: 15118125] [DOI: 10.1126/science.1099314]
Villa, L.L., Costa, R.L., Petta, C.A., Andrade, R.P., Ault, K.A., Giuliano, A.R., Wheeler, C.M., Koutsky, L.A., Malm, C., Lehtinen, M., Skjeldestad, F.E., Olsson, S.E., Steinwall, M., Brown, D.R., Kurman, R.J., Ronnett, B.M., Stoler, M.H., Ferenczy, A., Harper, D.M., Tamms, G.M., Yu, J., Lupinacci, L., Railkar, R., Taddeo, F.J., Jansen, K.U., Esser, M.T., Sings, H.L., Saah, A.J., and Barr, E. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6: 271-278. [PubMed: 15863374] [DOI: 10.1016/S1470-2045(05)70101-7]